Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
The new data demonstrates the potential to improve control of acute infection,…
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a…
